← All trials
NCT05074602
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 14, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2023
- First posted
- Oct 12, 2021
- Last posted
- Oct 12, 2021
- Enrollment
- 196
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.